Feature Jam has obtained a patent for its proprietary system that uses artificial intelligence to monitor abnormal movements that could indicate a risk of falls, strokes, or tremors associated with Parkinson’s disease. At the same time, it has initiated a clinical trial for the BlueJam platform.

The innovative SME, incubated by Bio4Dreams, specializes in developing advanced technologies aimed at improving the quality of life for vulnerable individuals, including the elderly.

In particular, BlueJam is a platform that combines a wearable device with AI-based software, designed to prevent falls, monitor tremors caused by Parkinson’s disease, and detect transient ischemic attacks and strokes.

Patented AI system for monitoring falls, strokes, and Parkinson’s disease

Feature Jam’s patent specifically relates to the method of collecting and processing data through AI to detect movement anomalies or deficits related to the risk of falls, ischemic attacks, strokes, and Parkinson’s disease.

This achievement confirms the system’s originality and innovative nature, and the SME has already started procedures to extend the patent to the Eurozone and the United States.

BlueJam in clinical trials for fall risk monitoring

As part of a research project on atrial fibrillation funded by the Friuli Venezia Giulia region, Feature Jam will launch a clinical trial for fall risk monitoring.

This trial represents a significant opportunity to further refine BlueJam and provide increasingly effective monitoring solutions, improving the safety and autonomy of the elderly.

📗 Learn more about Feature Jam and other companies in our portfolio.